A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium 68 satoreotide (Primary) ; Lutetium 177 satoreotide tetraxetan (Primary)
Indications Advanced breast cancer; Cancer; Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms SSTR2
Sponsors Ipsen

Most Recent Events

08 Oct 2020 Protocol amended to amend timepoints of primary endpoints due to early study termination.
28 Feb 2020 Status changed from withdrawn prior to enrolment to discontinued.
08 Jan 2020 Planned End Date changed from 13 Dec 2024 to 8 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight